A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
Hao Zhang(Cedars-Sinai Medical Center), Hyung L. Kim(Cedars-Sinai Medical Center)
Cited by 62
Related Papers
Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity
|Clinical Cancer Research|2021|30